Zofia Piotrowska, MD, MHS | Authors


Examining the Impact of the FLAURA Trial in EGFR-Mutant NSCLC

March 14, 2020

Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.

Erlotinib Plus Ramucirumab Show Promising Activity in EGFR+ Lung Cancer

November 26, 2019

Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the results from the phase III RELAY trial that investigated first-generation EGFR inhibitor erlotinib plus the VGEF-directed antibody ramucirumab in patients with EGFR-mutant lung cancer.